245 related articles for article (PubMed ID: 32948461)
1. Evaluation of naloxone furnishing community pharmacies in San Francisco.
Nguyen AM; Kearney TE; Apollonio DE
J Am Pharm Assoc (2003); 2020; 60(6):1050-1057.e1. PubMed ID: 32948461
[TBL] [Abstract][Full Text] [Related]
2. Pharmacists' naloxone services beyond community pharmacy settings: A systematic review.
Rawal S; Osae SP; Cobran EK; Albert A; Young HN
Res Social Adm Pharm; 2023 Feb; 19(2):243-265. PubMed ID: 36156267
[TBL] [Abstract][Full Text] [Related]
3. Implementation of hormonal contraceptive furnishing in San Francisco community pharmacies.
Chen L; Lim J; Jeong A; Apollonio DE
J Am Pharm Assoc (2003); 2020; 60(6):963-968.e2. PubMed ID: 32800456
[TBL] [Abstract][Full Text] [Related]
4. Pharmacist furnishing of naloxone in California: A follow-up analysis.
Puzantian T; Gasper JJ; Ramirez CM
J Am Pharm Assoc (2003); 2021; 61(5):e108-e112. PubMed ID: 34246575
[TBL] [Abstract][Full Text] [Related]
5. An observational study of the extent of naloxone furnishing in California Central Valley community pharmacies.
Banawis M; Mah G; Mohsin R; Pobre J; Tracy D; Song AV; Apollonio DE
J Am Pharm Assoc (2003); 2023; 63(2):566-573. PubMed ID: 36476261
[TBL] [Abstract][Full Text] [Related]
6. Preparing pharmacists to increase naloxone dispensing within community pharmacies under the Pennsylvania standing order.
Santa HM; Amirova SG; Ventricelli DJ; Downs GE; Nowalk AA; Pringle JL; Aruru M
Am J Health Syst Pharm; 2021 Feb; 78(4):327-335. PubMed ID: 33336254
[TBL] [Abstract][Full Text] [Related]
7. Pharmacy leaders' beliefs about how pharmacies can support a sustainable approach to providing naloxone to the community.
Donovan E; Bratberg J; Baird J; Burstein D; Case P; Walley AY; Green TC
Res Social Adm Pharm; 2020 Oct; 16(10):1493-1497. PubMed ID: 31983625
[TBL] [Abstract][Full Text] [Related]
8. Beliefs Associated with Pharmacy-Based Naloxone: a Qualitative Study of Pharmacy-Based Naloxone Purchasers and People at Risk for Opioid Overdose.
Donovan E; Case P; Bratberg JP; Baird J; Burstein D; Walley AY; Green TC
J Urban Health; 2019 Jun; 96(3):367-378. PubMed ID: 30747371
[TBL] [Abstract][Full Text] [Related]
9. Naloxone for opioid overdose prevention: pharmacists' role in community-based practice settings.
Bailey AM; Wermeling DP
Ann Pharmacother; 2014 May; 48(5):601-6. PubMed ID: 24523396
[TBL] [Abstract][Full Text] [Related]
10. Pharmacists and Naloxone: Barriers to Dispensing and Effectiveness of an Educational Outreach Program.
Hanson KA; Smart MH; Mandava MR; Carkovic E; Aslamy M; Lee TA; Pickard AS
J Am Pharm Assoc (2003); 2023; 63(2):608-613.e3. PubMed ID: 36631342
[TBL] [Abstract][Full Text] [Related]
11. Pharmacy on-site overdose protocols and prevention of overdose.
Green TC; Soipe A; Baloy B; Burstein D; Xuan Z; Tapper A; Walley AY; Case P; Bratberg J; Baird J
Subst Abus; 2022; 43(1):64-68. PubMed ID: 32186478
[TBL] [Abstract][Full Text] [Related]
12. The evaluation of mandatory alerts on long-acting opioid prescriptions and the use of a community pharmacy naloxone protocol.
Coffman R; Johnson A; Frede S; Pleiman M; Johnson K
J Am Pharm Assoc (2003); 2022; 62(4S):S35-S40.e1. PubMed ID: 34930681
[TBL] [Abstract][Full Text] [Related]
13. Pharmacy naloxone codispensing: A mixed methods study of practices and perspectives under a statewide standing order program.
Pollini RA; Slocum S; Ozga JE; Joyce R; Xuan Z; Green TC; Walley AY
J Am Pharm Assoc (2003); 2022; 62(5):1546-1554. PubMed ID: 35450833
[TBL] [Abstract][Full Text] [Related]
14. Revisiting pharmacy-based naloxone with pharmacists and naloxone consumers in 2 states: 2017 perspectives and evolving approaches.
Green TC; Donovan E; Klug B; Case P; Baird J; Burstein D; Tapper A; Walley AY; Bratberg J
J Am Pharm Assoc (2003); 2020; 60(5):740-749. PubMed ID: 32334964
[TBL] [Abstract][Full Text] [Related]
15. The feasibility of pharmacy-based naloxone distribution interventions: a qualitative study with injection drug users and pharmacy staff in Rhode Island.
Zaller ND; Yokell MA; Green TC; Gaggin J; Case P
Subst Use Misuse; 2013 Jun; 48(8):590-9. PubMed ID: 23750660
[TBL] [Abstract][Full Text] [Related]
16. Study protocol for the Respond to Prevent Study: a multi-state randomized controlled trial to improve provision of naloxone, buprenorphine and nonprescription syringes in community pharmacies.
Green TC; Bratberg J; Irwin AN; Boggis J; Gray M; Leichtling G; Bolivar D; Floyd A; Al-Jammali Z; Arnold J; Hansen R; Hartung D
Subst Abus; 2022; 43(1):901-905. PubMed ID: 35213293
[TBL] [Abstract][Full Text] [Related]
17. Attitudes and availability: A comparison of naloxone dispensing across chain and independent pharmacies in rural and urban areas in Alabama.
Sisson ML; McMahan KB; Chichester KR; Galbraith JW; Cropsey KL
Int J Drug Policy; 2019 Dec; 74():229-235. PubMed ID: 31698165
[TBL] [Abstract][Full Text] [Related]
18. An observational survey assessing the extent of PrEP and PEP furnishing in San Francisco Bay Area pharmacies.
Bellman R; Mohebbi S; Nobahar N; Parizher J; Apollonio DE
J Am Pharm Assoc (2003); 2022; 62(1):370-377.e3. PubMed ID: 34429253
[TBL] [Abstract][Full Text] [Related]
19. Impact of student pharmacist-led naloxone academic detailing at community pharmacies in Texas.
Evoy KE; Groff L; Hill LG; Godinez W; Gandhi R; Reveles KR
J Am Pharm Assoc (2003); 2020; 60(1):81-86. PubMed ID: 31669417
[TBL] [Abstract][Full Text] [Related]
20. "Like it was just everyday business": A qualitative study of pharmacy-based naloxone and syringe customer experience.
Gray M; Shin SS; Silcox J; Flores D; Bolivar D; Irwin AN; Floyd AS; Bratberg J; Boggis JS; Hartung DM; Green TC
J Am Pharm Assoc (2003); 2023; 63(3):838-846. PubMed ID: 36872182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]